Findings

What do systematic reviews say?

4,929 questions · 15,174 findings · 2,372 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Test · adults with glioma Role: 1p/19q status is used for diagnosis, to inform treatment decisions and to give information on prognosis…

The review found no eligible studies for this question.

1 finding from 1 review

Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Berotralstat vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

C1 esterase inhibitor vs placebo or active control

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

Adverse events (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Differences in quality of life ( · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lanadelumab vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lanadelumab vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Cemented modern unipolar hemiarthroplasty · older adults (> 60 years of age) with intracapsular hip fractures; most fractures in the included studies were displaced

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for treating intracapsular hip fractures in older adults: a network meta‐analysis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found